Trial Profile
A phase II study of Efpeglenatide for non-alcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 18 Dec 2017 New trial record
- 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.